Analyst Consensus ?
ConsensusHold33 ratings
Bullish1648.5%
Neutral1648.5%
Bearish13.0%
Becton, Dickinson and Company · BDX · FY2024 Q4 · Calendar Q4 2024
BD maintains FY25 outlook while investing in connected care
The supplied analysis supports a constructive but qualified outlook: solid FY24 execution, new product launches and connected-care investments provide growth support, while China, bioscience-pharma demand and integration execution are important offsets.
Reported Before market openNYSEHealthcare
$50.63B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$3.81
Consensus $3.77
EPS surprise
+1.1%
Reported versus consensus
Reported revenue
$5.44B
Consensus $5.38B
Revenue surprise
+1.1%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-5.4%
Event window
SPY move
+0.8%
Same window
Abnormal move
-6.2%
Stock minus SPY
Volume
3.7×
Versus trailing sessions
Subsequent drift
-3.1%
Up to 20 sessions
BDXSPY benchmark
Ask FN2 about BDX FY2024 Q4
Transcript, numbers and history already loaded
Why did BDX fall 5.4% after beating EPS estimates in FY2024 Q4?What changed in BDX's guidance and outlook in FY2024 Q4?Give me the bull and bear case for BDX after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis shifts the focus from the prior quarter's raised FY24 outlook and pending Critical Care acquisition to maintained FY25 guidance, a broader advanced-monitoring platform and a larger stated product-launch pipeline. China and bioscience-pharma caution remain central risks.
Guidance delta
Management maintained its outlook, targeting FY25 revenue of $21.9-$22.1 billion and adjusted EPS of $14.25-$14.60, with 100 basis points of additional operating-margin expansion.
Key takeaways
- FY24 ended with 5% organic revenue growth, 120 basis points of margin expansion and $3.1 billion of free cash flow.
- Management highlighted AI-enabled devices, biologic drug delivery, advanced patient monitoring and PureWick as growth drivers.
- China and bioscience-pharma markets remain areas of caution, while more than 25 new product launches are planned for FY25.
Management priorities
- Execute the FY25 product-launch pipeline, including next-generation Pyxis, advanced monitoring and PureWick offerings.
- Expand AI, automation and connected medication-management capabilities.
- Maintain disciplined capital allocation, including deleveraging, dividends and the stated share-repurchase program.
Follow BDX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$183.75Current
$159Low
$199.13Average
$235.85High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 12, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| B of A Securities | Neutral | Neutral | Maintain | Aug 31, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Aug 13, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 7, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 7, 2026 |
| TD Cowen | Hold | Hold | Maintain | Aug 5, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 11, 2026 |
| Argus Research | Buy | Buy | Maintain | Mar 23, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Feb 10, 2026 |
| Jefferies | Buy | Buy | Maintain | Feb 10, 2026 |
| Stifel | Buy | Buy | Maintain | Jan 7, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Dec 2, 2025 |
| William Blair | Market Perform | Outperform | Downgrade | May 1, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Aug 2, 2024 |
| Keybanc | Overweight | Sector Weight | Upgrade | Apr 12, 2023 |
| Goldman Sachs | Buy | Buy | Maintain | Nov 23, 2022 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Feb 4, 2022 |
| UBS | Neutral | Neutral | Maintain | Aug 10, 2020 |
| CFRA | Hold | Hold | Maintain | May 8, 2020 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Feb 7, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Dec 16, 2019 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 10, 2019 |
| Deutsche Bank | Buy | Buy | Maintain | Dec 7, 2018 |
| Bank of America | Neutral | Neutral | Maintain | Nov 5, 2014 |
| Canaccord Genuity | Hold | Hold | Maintain | Oct 7, 2014 |
| Argus | Buy | Buy | Maintain | Oct 7, 2014 |
| PiperJaffray | Overweight | Neutral | Upgrade | Sep 18, 2013 |
| ISI Group | Buy | Buy | Maintain | Jun 25, 2013 |
| Macquarie | Outperform | Neutral | Upgrade | May 10, 2013 |
| Mizuho | Neutral | Buy | Downgrade | Jan 22, 2013 |
| Leerink Swann | Market Perform | Outperform | Downgrade | Aug 3, 2012 |
| CLSA | Underperform | Outperform | Downgrade | Aug 3, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $183.75. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Christopher Pasquale | $165 | $179.62 | -10.2% | Oct 7, 2026 |
| RBC Capital | Analyst unavailable | $190 | $184.04 | +3.4% | Aug 13, 2026 |
| Stifel Nicolaus | Analyst unavailable | $195 | $176.07 | +6.1% | Aug 7, 2026 |
| RBC Capital | Shagun Singh | $180 | $176.25 | -2.0% | Aug 7, 2026 |
| Jefferies | Analyst unavailable | $210 | $176.91 | +14.3% | Aug 6, 2026 |
| UBS | Analyst unavailable | $190 | $158.92 | +3.4% | Jul 28, 2026 |
| Evercore ISI | Analyst unavailable | $180 | $154.6 | -2.0% | Jul 6, 2026 |
| Barclays | Analyst unavailable | $204 | $149.43 | +11.0% | May 11, 2026 |
| Piper Sandler | Jason Bednar | $159 | $154.82 | -13.5% | Apr 17, 2026 |
| RBC Capital | Analyst unavailable | $175 | $155.43 | -4.8% | Apr 14, 2026 |
| Goldman Sachs | David Roman | $167 | $154.42 | -9.1% | Apr 10, 2026 |
| RBC Capital | Shagun Singh | $172 | $170.14 | -6.4% | Feb 10, 2026 |
| Barclays | Matt Miksic | $202 | $207.39 | +9.9% | Feb 10, 2026 |
| Piper Sandler | Analyst unavailable | $170 | $207.39 | -7.5% | Feb 10, 2026 |
| Piper Sandler | Jason Bednar | $161.16 | $159.91 | -12.3% | Jan 28, 2026 |
| Stifel Nicolaus | Analyst unavailable | $169.03 | $161.45 | -8.0% | Jan 7, 2026 |
| RBC Capital | Analyst unavailable | $165.09 | $154.39 | -10.2% | Dec 17, 2025 |
| Morgan Stanley | Patrick Wood | $165.09 | $150.8 | -10.2% | Dec 2, 2025 |
| Piper Sandler | Jason Bednar | $204.4 | $159.06 | +11.2% | Apr 23, 2025 |
| Evercore ISI | Vijay Kumar | $227.99 | $189.54 | +24.1% | Oct 1, 2024 |
| Citigroup | Joanna Wuensch | $216.19 | $190.2 | +17.7% | Oct 1, 2024 |
| Raymond James | Jayson Bedford | $212.26 | $187.96 | +15.5% | Aug 2, 2024 |
| Wells Fargo | Larry Biegelsen | $220.13 | $185.54 | +19.8% | Aug 2, 2024 |
| Evercore ISI | Becton Dickinson | $224.06 | $180.24 | +21.9% | Jul 2, 2024 |
| Goldman Sachs | David Roman | $215.41 | $176.94 | +17.2% | May 30, 2024 |
| Barclays | Matt Miksic | $245.28 | $184.5 | +33.5% | May 6, 2024 |
| Argus Research | David Toung | $235.85 | $190.83 | +28.4% | Apr 8, 2024 |
| Morgan Stanley | Analyst unavailable | $227.99 | $202.92 | +24.1% | Jan 6, 2023 |
| Citigroup | Analyst unavailable | $196.54 | $194.65 | +7.0% | Dec 12, 2022 |
| Goldman Sachs | Analyst unavailable | $213.84 | $185.9 | +16.4% | Nov 23, 2022 |
| Goldman Sachs | Analyst unavailable | $250.79 | $210.01 | +36.5% | Aug 16, 2022 |
| Stifel Nicolaus | Analyst unavailable | $220.13 | $187.4 | +19.8% | Jul 18, 2022 |
| Morgan Stanley | Analyst unavailable | $213.84 | $187.61 | +16.4% | Jul 15, 2022 |
| Citigroup | Analyst unavailable | $184.75 | $193.13 | +0.5% | Jul 11, 2022 |
| Wells Fargo | Larry Biegelsen | $231.92 | $197.26 | +26.2% | Jun 25, 2022 |
| Morgan Stanley | Analyst unavailable | $221.7 | $197.95 | +20.7% | May 6, 2022 |
| Piper Sandler | Analyst unavailable | $200.47 | $204.12 | +9.1% | May 6, 2022 |
| Bank of America Securities | Travis Steed | $227.99 | $209.27 | +24.1% | Mar 3, 2022 |
| Piper Sandler | Jason Bednar | $208.33 | $206.71 | +13.4% | Feb 3, 2022 |
Track every rating change on BDX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationOperating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems.…
Historical context
All BDX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
Get the BDX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-12T03:10:41.272669+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-12T03:10:41.269904+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-12. For educational purposes only; not investment advice.